Amoxicillin Pulsatile Release Multiparticluate Sprinkle — Competitive Intelligence Brief

Amoxicillin Pulsatile Release Multiparticluate Sprinkle (Amoxicillin Pulsatile Release Multiparticluate Sprinkle) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (penicillin). Area: Infectious Disease.

phase 3 Beta-lactam antibiotic (penicillin) Penicillin-binding proteins (PBPs) Infectious Disease Small molecule

Target snapshot

Amoxicillin Pulsatile Release Multiparticluate Sprinkle (Amoxicillin Pulsatile Release Multiparticluate Sprinkle) — Advancis Pharmaceutical Corporation. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, delivered via a pulsatile release multiparticulate sprinkle formulation for modified pharmacokinetics.

Comparator set (1 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Amoxicillin Pulsatile Release Multiparticluate Sprinkle TARGET	Amoxicillin Pulsatile Release Multiparticluate Sprinkle	Advancis Pharmaceutical Corporation	phase 3	Beta-lactam antibiotic (penicillin)	Penicillin-binding proteins (PBPs)
Benzathine Penicilllin G	Benzathine Penicilllin G	Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia	phase 3	Beta-lactam antibiotic (penicillin)	Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (penicillin) class)

1. Advancis Pharmaceutical Corporation · 1 drug in this class
2. Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · 1 drug in this class